<DOC>
	<DOCNO>NCT01239797</DOCNO>
	<brief_summary>The purpose study determine whether addition Elotuzumab Lenalidomide/low-dose Dexamethasone increase progression free survival ( PFS ) .</brief_summary>
	<brief_title>Phase III Study Lenalidomide Dexamethasone With Without Elotuzumab Treat Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Documented progression recent line therapy 13 prior line therapy Measurable disease Life expectancy ≥3 month Prior treatment Lenalidomide permit : 1 . Best response achieve ≥Partial Response ( PR ) 2 . Patient refractory 3 . Patient discontinue due Grade ≥3 related adverse event 4 . Subject receive 9 cycle Lenalidomide least 9 month last dose Lenalidomide progression Subjects nonsecretory oligosecretory serum free lightchain myeloma Active plasma cell leukemia Known Human immunodeficiency virus ( HIV ) infection active hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>